tbuckley/cabot-search huggingface dataset:
PHILADELPHIA—ALBUQUERQUE—CHICAGO
Journal: JAMA (1960)

Another name has been added to the masthead ofThe Journal. Another position of major responsibility has been incorporated in the structure of the Editorial Division. Dr. Burgess Lee Gordon became a full-time member of our staff a fortnight ago when he assumed the duties and anticipated the privileges of Associate Editor ofThe Journal. One of his last educational assignments, before moving to Chicago, was the detailed supervision of a treatise entitled "Clinical Cardiopulmonary Physiology," sponsored by the American College of Chest Physicians. This is but one of many editorial assignments that reflect credit upon his talents in this field of medicine. Since the completion of his formal medical training in the early 1920's, Burgess has served as Associate Editor of the Oxford System of Medicine and as a member of the Editorial Board of<i>Roentgenology of the Chest</i>. It was clear to those of us who were interested
Correction
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Figure
Authors: Kevin Alexander, Sharmila Dorbala
Journal: JAMA Cardiology (2021)

Baris Gencer, MD; François Mach, MD; Sabina A. Murphy, MPH; Gaetano M. De Ferrari, MD; Kurt Huber, MD; Basil S. Lewis, MD; Jorge Ferreira, MD; Christopher E. Kurtz, MD; Huei Wang, PhD; Narimon Honarpour, MD; Anthony C. Keech, MD; Peter S. Sever, MD; Terje R. Pedersen, MD; Marc S. Sabatine, MD, MPH; Robert P. Giugliano, MD, SM
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Authors: Matthias Danz, Jochen Hinkelbein
Journal: New England Journal of Medicine (2016)

race.The first cases of hyponatremia appeared in the cluster of participants who finished in the 9th hour of the race; cases of critical hyponatremia occurred in the clusters of participants who finished in the 12th and 14th hours of the race.A previous study involving marathon runners showed that 12 to 13% of participants had hyponatremia and that the incidence of critical hyponatremia was 0.5 to 1%. 1 In contrast, the observed incidence of hyponatremia in longdistance triathlons was 10.6%.The incidence of critical hyponatremia was 0.3% (approximately half the incidence seen among marathoners).Our data show that exercise-associated hyponatremia occurs in a considerable percentage of long-distance triathletes.Female triathletes with a racing time of 9 hours or more appear to be the most susceptible to hyponatremia.
AIDS vaccines inch closer to useful existence
Authors: M. F. Goldsmith
Journal: JAMA (1991)

CANDIDATE vaccines for the human immunodeficiency virus (HIV) are now being tested for safety and immunogenicity in several clinical trials in the United States and abroad. Notwithstanding the formidable host of factors that militate against development of an effective prophylactic for the acquired immunodeficiency syndrome (AIDS), a growing number of researchers are hopeful about eventual success. Under the aegis of the National Institute of Allergy and Infectious Diseases (NIAID) or another governmental agency, investigators are working at more than a dozen academic medical centers, most as part of NIAID's National Cooperative Vaccine Development Groups or Vaccine Evaluation Units. The vaccines that are described herein have all been tested in animals— most in monkeys and some in chimpanzees—and found to be safe and immunogenic to some degree against HIV. Only two so far have been found to protect against infection. The urgent need for an AIDS vaccine has accelerated their movement
Abstract 196: Genetically Modified Human Mesenchymal Stromal Cells (MSCs) Help Improve Glucose Homeostasis by Reducing Inflammation and Promotes Browning of Visceral Fat
Authors: Sabyasachi Sen, Cleyton Domingues, Nabanita Kundu, Neeki Ahmadi
Journal: Circulation Research (2017)

Background: MSCs are multipotent cells that can home-in to a site of inflammation. Upregulation of specific antioxidants in MSCs reduces intracellular inflammation and ROS formation in a hyperglycemic condition. Hypothesis: Antioxidant over-expressed MSCs will reach fat depots, reduce local &amp; systemic inflammation and improve glucose homeostasis in diet-induced obese (DIO, 60% and 45% fat diet) hyperglycemic mouse models. Methods: We used GFP-containing adenoviral constructs to upregulate intracellular (SOD1, SOD2, Catalase) and extracellular (SOD3) antioxidants in human adipose-derived MSCs. The modified MSCs were delivered in DIO mice. Results: In-vitro, SOD2 (mitochondrial anti-oxidant) upregulation showed reduced inflammatory markers IL6 and TNFa mRNA while PCG1A mRNA (a gene upstream of UCP1), upregulated. SOD2 upregulated MSC delivery in both DIO models demonstrated improved glucose tolerance test (GTT) at week 4 compared to SOD1-MSC and Null-MSC (control). Catalase-MSC delivery not only improved GTT but also improved insulin tolerance test (ITT) in 60% DIO mice. Interestingly, RT-PCR of pericardial fat showed significant increases in mRNA expression of both UCP1 (25-100,000-fold) and PRDM-16 (2-10-fold) in both DIO mice models that received antioxidants upregulated MSCs, compared to mice receiving Null MSCs. For omental fat, an increase in mRNA expression of UCP1 was observed in 60% fat DIO mice (1,000-6000 fold) for SODs 1-3 and catalase, while for 45% DIO mice only those receiving SOD1 &amp; SOD2 upregulated MSCs presented UCP1 mRNA upregulation (1,000 to 11,000-fold). Omental Fat histology showed less hyperplastic fat with SOD2 and Catalase-MSCs. UCP1 staining of omental fat was also positive with SOD2-MSC. Inflammatory molecules such as IL-6 and TNF alpha levels by ELISA, were reduced with SOD2-MSC in 60% DIO mice model. Conclusion: We conclude that delivery of antioxidant upregulated MSCs to the inflamed adipocyte depots in diabetic DIO models appear to upregulate UCP1 and PRDM-16 in visceral fat while reducing systemic inflammatory markers, which may explain improvements noted in GTT and ITT. Delivery of modified MSC is a novel &amp; robust therapeutic tool that improves glucose homeostasis in diet induced diabetes.
Endocrinology
Authors: Robert L. Young
Journal: JAMA (1980)

Among the many advances in endocrinology in the past decade, three have been singled out for discussion: the discovery of cellular receptors, the concept that diabetes is more than one disease, and the newer aspects of pituitary therapy with emphasis on hyperprolactinemic states. Advances in these areas have profoundly altered our current concepts and treatment of disease. <h3>Discovery of Cell Receptors</h3> The identification of cell receptors has been central in increasing our understanding of familial hypercholesterolemia. One form of this disorder seems to result from a defect in low-density lipoprotein (LDL)-cholesterol receptors, which in turn diminishes the cell's ability to internalize cholesterol.<sup>1</sup>Since intracellular LDL-cholesterol concentration regulates the feedback suppression of endogenous cholesterol synthesis, this inability to internalize LDL results in unabated production of cholesterol by the cells. It has been estimated that the heterozygous form of familial hypercholesterolemia occurs in one of every 500 people in the general population.
Abstract P143: Cardiovascular Health Among Asian Americans, NHANES 2011-2014
Authors: Jing Fang, Zefeng Zhang, Carma Ayala, Angela Thompson-Paul, Fleetwood Loustalot
Journal: Circulation (2018)

Background: Non-Hispanic Asian Americans (AA) are one of the fastest growing populations in the U.S., yet little information is known about the cardiovascular health (CVH) of this group. The objective of this study was to assess the CVH of AA using a nationally representative survey. Methods: Merging data from the National Health and Nutrition Examination Surveys (NHANES) in 2011-2012 and 2013-2014, we examined 7 metrics of CVH using national guidelines and recommendations: not smoking, normal weight (body mass index, BMI &lt;25 kg/m 2 ) , adequate physical activity, healthy diet, normal blood cholesterol , normal blood glucose and normal blood pressure. Each CVH metric was weighted evenly, with scores for each metric being a 0 (not meeting standards) or 1 (meeting current standards), and the metrics were summed for a total score. Ideal CVH (ICVH) was defined as the percentage of those meeting recommendations for 6-7 metrics, and poor CVH (PCVH) defined as those meeting only 0-2. We compared the prevalence of ICVH and PCVH between non-Hispanic whites (NHW) and AA, as well as among AA by birthplace and years living in the U.S. We also assessed the adjusted prevalence ratios (APR, 95% Confidence Intervals [CI]) of ICVH for AA, using NHW as referent, controlling for age, sex, education, and health insurance status. Additional sensitivity analyses were performed using a previously established Asian-specific normal weight cut-point (BMI&lt;23 kg/m 2 ) for AA. Results: In adjusted models, AA were more likely to not smoke, have a normal weight, report a healthy diet and have normal blood pressure, compared with NHWs. However, NHWs were more likely to have normal blood glucose compared with AA, and no difference was identified with reported physical activity and blood cholesterol. The adjusted prevalence of ICVH was 9.2% for AA and 5.7% for NHWs (p&lt;0.01). The adjusted percentage for PCVH was 26.6% for AA and 33.5% for NHWs (p&lt;0.01). AA were significantly more likely to have ICVH (APR 1.41, 95% CI: 1.25-1.60) compared to NHW, but there was no difference in ICVH comparing US-born and foreign-born, nor by years living in the US. Additional sensitivity analyses using lower BMI thresholds for AA, consistently found a higher percentage of normal weight AA compared with NHW (36.4% vs 30.4, p&lt;0.01); with no differences in the adjusted prevalence of ICVH (6.7% vs 5.7%, p=0.4) and PCVH (30.8% vs 33.5%, p=0.2) between AA and NHW (APR 1.18, 95% CI: 0.84-1.66). Conclusion: AA currently account for 5.3% of adult population in the US, and have been identified as one of the fasting growing minority populations. In this study, AA had a higher prevalence of overall ICVH compared with NHWs; however, when using a lower BMI threshold for AA as recommended by some, there was no difference of ICVH between AA and NHW. Using unique risk scores for AA may better identify AA with less than ideal cardiovascular health.
Massachusetts Medical Society
Authors: John Figgis Jewett
Journal: New England Journal of Medicine (1972)

COMMITTEE ON MATERNAL WELFAREAccouchement ForcéA 41-year-old gravida 5, para 4, delayed application for prenatal care until 23 weeks because her husband died. At 36. weeks she had "Asian flu," but otherwise the prenatal care was unremarkable, as had been all four previous pregnancies in which no labor lasted longer than two hours.At 38 weeks the membranes spontaneously ruptured, and the patient was admitted to the hospital in 12 hours with contractions three minutes apart, the presenting part high and the cervix dilated to admit 1 1/2 fingers. Respiratory symptoms were still present, and the pulse rate was . . .
COMMUNITY HEALTH WEEK
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk of metabolic syndrome and fatty liver in gastric cancer survivors: A propensity score-matched analysis.
Authors: Hyojin Park
Journal: Journal of Clinical Oncology (2022)

266 Background: With the recent development in cancer treatments, the number of cancer survivors is rapidly increasing. The aim of this study was to investigate the prevalence and risk of metabolic syndrome and fatty liver in GC survivors compared with that in non-cancer (NC) subjects. We also analysed the risk for metabolic dysfunction-associated fatty liver disease (MAFLD) 8 in GC survivors compared with that in NC subjects. Methods: In this cross-sectional study, participants who visited Gangnam Severance Hospital from 2014 to 2019 for health check-ups were enrolled. After age- and sex-matched 1:4 propensity score matching, 119 GC survivors and 476 NC subjects were included. GC survivors were divided into operated gastric cancer survivors (OpGC) (n = 95) and non-operated survivors (non-OpGC) (n = 24). MetS was diagnosed by metabolic components and FL was assessed by ultrasonography. Results: MetS was observed in 21.0% of GC survivors and 30.5% of NC subjects, and in 13.7% of OpGC survivors and 50.0% of non-OpGC survivors. FL was observed in 25.2% of GC survivors and 37.6% of NC subjects, and in 21.1% of OpGC survivors and 41.7% of non-OpGC survivors. After adjusting for age, sex, MetS risk was significantly lower in OpGC survivors (odds ratio [OR] = 0.377, 95% confidence interval [CI]: 0.200-0.711, P = 0.003). FL risk was significantly lower in OpGC survivors (OR = 0.467, 95% CI: 0.267–0.816, P = 0.007), but not in non-OpGC survivors, compared with NC subjects. Risk of metabolic dysfunction-associated fatty liver disease was significantly lower in OpGC survivors (OR = 0.412, 95% CI: 0.233–0.729, P = 0.002) compared with NC subjects. Conclusions: OpGC survivors showed a lower risk of MetS and FL compared with NC subjects. These associations can be explored to ensure timely medical intervention in GC survivors.
PIONEER: A multicenter, open-label, randomized phase II trial of second-line apatinib plus chemotherapy versus chemotherapy alone in gastric and gastroesophageal junction adenocarcinoma (GA/GEA) refractory to or intolerant of prior anti-PD-1 therapy.
Authors: Dandan Yu, Hongli Liu, Jianli Hu, Hong Ma, Jun Xue, Junli Liu, Jing Wang, Zhenyu Lin, Min Jin, Shengli Yang, Lei Zhao, Tao Zhang
Journal: Journal of Clinical Oncology (2022)

TPS361 Background: Immunotherapy has revolutionized landscape of cancer treatment. Anti-PD-1 therapy provides significant clinical benefit and durable response in various types of cancers. However, clinical response rate to anti-PD-1 therapy has been reported to vary from 10%-40% in different cancers. And, a substantial number of patients who initially responded to anti-PD-1 therapy developed acquired resistance over time. Few effective treatment options are available for such patients. Previous studies indicated that prior anti-PD-1 exposure might increase tumor response to anti-VEGFR2 (ramucirumab) plus chemotherapy in patients with advanced/metastatic GA/GEA. Apatinib, a highly selective VEGFR2 inhibitor, has been demonstrated to be efficacious and well-tolerated for the treatment of chemotherapy-refractory advanced GA/GEA. The PIONEER study is designed to evaluate the efficacy and safety of second-line apatinib plus chemotherapy in GA/GEA patients after prior anti-PD-1 therapy. Methods: PIONEER (NCT05029453) is a multicenter, open label, randomized phase II trial of second-line apatinib plus chemotherapy versus chemotherapy alone in patients with histologically confirmed advanced GA/GEA refractory to or intolerant of prior anti-PD-1 therapy for no less than 2 months. Patients must be ≥18 years of age, with ECOG PS of 0 or 1, and have measurable disease per RECIST v1.1, adequate organ function, and expected survival time of ≥12 weeks. Patients who previously received antiangiogenic agents (such as apatinib or ramucirumab), had concurrent or previous tumor history within past 3 years, or underwent anti-tumor therapy within 4-week of recruitment will be excluded. Approximately 60 patients will be randomized (1:1) to receive apatinib (500 mg orally qd) plus chemotherapy (docetaxel 60/75 mg/m 2 , d1 q3w, and nab-paclitaxel 125 mg/m 2 d1 &amp; d8 q3w or 260 mg/m 2 d1 q3w) or chemotherapy alone until disease progression, unacceptable toxicity, or death. The primary endpoint is progression-free survival (PFS). The secondary endpoints are overall response rate (ORR), disease control rate (DCR), duration of response (DOR), overall survival (OS), and adverse events (AEs) per NCI CTCAE v5.0. Patient enrollment has just started and is expected to be completed in June 2022. Clinical trial information: NCT05029453.
Erratum
Journal: JNCI Journal of the National Cancer Institute (1997)

“Preliminary Results From the Cancer Research Campaign Trial Evaluating Tamoxifen Duration in Women Aged Fifty Years or Older With Breast Cancer,” by the Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group [J Natl Cancer Inst 1996;88:1834-9 (Issue 24)]. In Table 1, the median age in the 5-year tamoxifen group should be 61 years, not 51. The Journal regrets the error.
Security Analysis
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Host transcriptome signatures in human faecal-washes predict histological remission in patients with IBD
Authors: Bella Ungar, Miri Yavzori, Ella Fudim, Orit Picard, Uri Kopylov, Rami Eliakim, Dror Shouval, Yishai Levin, Alon Savidor, Shani Ben-Moshe, Rita Manco, Stav Dan, Adi Egozi, Keren Bahar Halpern, Chen Mayer, Iris Barshack, Shomron Ben-Horin, Shalev Itzkovitz
Journal: Gut (2022)

Colonoscopy is the gold standard for evaluation of inflammation in inflammatory bowel diseases (IBDs), yet entails cumbersome preparations and risks of injury. Existing non-invasive prognostic tools are limited in their diagnostic power. Moreover, transcriptomics of colonic biopsies have been inconclusive in their association with clinical features.To assess the utility of host transcriptomics of faecal wash samples of patients with IBD compared with controls.In this prospective cohort study, we obtained biopsies and faecal-wash samples from patients with IBD and controls undergoing lower endoscopy. We performed RNAseq of biopsies and matching faecal-washes, and associated them with endoscopic and histological inflammation status. We also performed faecal mass-spectrometry proteomics on a subset of samples. We inferred cell compositions using computational deconvolution and used classification algorithms to identify informative genes.We analysed biopsies and faecal washes from 39 patients (20 IBD, 19 controls). Host faecal-transcriptome carried information that was distinct from biopsy RNAseq and faecal proteomics. Transcriptomics of faecal washes, yet not of biopsies, from patients with histological inflammation were significantly correlated to one another (p=5.3×10-12). Faecal-transcriptome had significantly higher statistical power in identifying histological inflammation compared with transctiptome of intestinal biopsies (150 genes with area under the curve >0.9 in faecal samples vs 10 genes in biopsy RNAseq). These results were replicated in a validation cohort of 22 patients (10 IBD, 12 controls). Faecal samples were enriched in inflammatory monocytes, regulatory T cells, natural killer-cells and innate lymphoid cells.Faecal wash host transcriptome is a statistically powerful biomarker reflecting histological inflammation. Furthermore, it opens the way to identifying important correlates and therapeutic targets that may be obscured using biopsy transcriptomics.
Bilateral Testicular Mass Presenting as a Rare Manifestation of Extramedullary Plasmacytoma on 18F-FDG PET/CT
Authors: Caner Civan, Evsen Apaydin Arikan, Duygu Has Simsek, Oner Sanli, Serkan Kuyumcu
Journal: Clinical Nuclear Medicine (2022)

We present the case of a 48-year-old man diagnosed with metastatic Ewing sarcoma who was referred for 18F-FDG PET/CT for treatment response evaluation following chemoradiotherapy. The patient also had complaints of new-onset testicular swelling at the time of imaging. Although the metastatic bone disease showed a complete metabolic response to treatment, 18F-FDG PET/CT demonstrated significantly increased metabolic activity in bilateral testicular mass. Consequently, the patient underwent bilateral orchiectomy, and histopathologic examination revealed bilateral testicular plasmacytoma, a rare manifestation of extramedullary plasmacytoma.
Coronary sinus oxygen saturation (SVO2) as a marker of myocardial ischemia Yves Gallais, St�phane Champagne, Jin Bo Su, Lucien Sambin, Bertrand Crozatier, Luc Hittinger. Inserm U400, Creteil, France, Anesthesiology Department, J Rostand Hospital, Ivry/Seine, France
Journal: Journal of the American College of Cardiology (2001)